论文部分内容阅读
目的探讨盐酸氨溴索雾化吸入治疗小儿病毒性上呼吸道感染的临床效果。方法将60例病毒性上呼吸道感染患儿随机均分为观察组(盐酸氨溴索雾化吸入)和对照组(利巴韦林颗粒口服+盐酸氨溴索静脉滴注),检测两组患儿治疗前后TNF-α、IL-6、C反应蛋白(CRP)、白细胞及中性粒细胞水平,记录患儿开始退热时间、完全退热时间、治疗总有效率及不良反应。结果两组治疗后TNF-α、IL-6、CRP、白细胞及中性粒细胞水平均低于治疗前(P<0.05);与对照组相比,观察组患儿开始退热时间、完全退热时间缩短(P<0.01),治疗后TNF-α、IL-6、CRP、白细胞及中性粒细胞水平降低(P<0.05);观察组治疗总有效率为86.67%,高于对照组的56.67%(P<0.01);两组患儿治疗期间均无严重不良反应发生。结论采用盐酸氨溴索雾化吸入治疗小儿病毒性上呼吸道感染的疗效显著且安全。
Objective To investigate the clinical effect of inhalation of ambroxol hydrochloride inhalation on pediatric viral upper respiratory tract infection. Methods Sixty children with viral upper respiratory tract infection were randomly divided into observation group (inhalation of ambroxol hydrochloride atomization) and control group (oral administration of ribavirin granules + ambroxol hydrochloride intravenous injection) The levels of TNF-α, IL-6, C-reactive protein (CRP), leukocyte and neutrophil in children before and after treatment were recorded. The onset of fever, complete antipyretic time, total effective rate and adverse reactions were recorded. Results After treatment, the levels of TNF-α, IL-6, CRP, leukocyte and neutrophil in both groups were lower than those before treatment (P <0.05). Compared with the control group, (P <0.01). After treatment, the levels of TNF-α, IL-6, CRP, leukocyte and neutrophil decreased (P <0.05). The total effective rate of the observation group was 86.67%, which was higher than that of the control group 56.67% (P <0.01). No serious adverse reactions occurred in both groups during treatment. Conclusion The inhalation of ambroxol hydrochloride inhalation for the treatment of pediatric viral upper respiratory tract infection is effective and safe.